A Phase I trial evaluating XmAb-20717, a PD-1 x CTLA-4 dual checkpoint inhibitor for the treatment of multiple oncology indications.
Phase of Trial: Phase I
Latest Information Update: 11 Jan 2018
At a glance
- Drugs XmAb-20717 (Primary)
- Indications Cancer
- Focus Adverse reactions
- 11 Jan 2018 New trial record
- 05 Jan 2018 According to a Xencor media release, the company is planning to initiate this trial in 2018.